ProPhase Labs, Inc. (PRPH)
Automate Your Wheel Strategy on PRPH
With Tiblio's Option Bot, you can configure your own wheel strategy including PRPH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PRPH
- Rev/Share 0.3308
- Book/Share 0.3593
- PB 0.9712
- Debt/Equity 3.3419
- CurrentRatio 0.9534
- ROIC -1.2009
- MktCap 14497879.0
- FreeCF/Share -0.9013
- PFCF -0.786
- PE -0.1338
- Debt/Assets 0.3888
- DivYield 0
- ROE -1.588
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
ProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic Platform
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
UNIONDALE, NY, June 06, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced the formation of its Clinical Science Advisory Board to support the clinical adoption and commercialization of its breakthrough BE-SmartTM molecular test for esophageal disease. The advisory board will provide expert strategic guidance as ProPhase leads the regulatory and commercialization pathway for BE-Smart, with the goal of establishing a new clinical and economic standard in the early detection and management of esophageal cancer risk.
Read More
ProPhase Labs, Inc. (PRPH) Q1 2025 Earnings Call Transcript
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Neutral
ProPhase Labs, Inc. (NASDAQ:PRPH ) Q1 2025 Earnings Conference Call May 20, 2025 10:00 AM ET Company Participants Noella Alexander-Young - Virtual Event Moderator, Renmark Financial Communications Ted Karkus - Chief Executive Officer Noella Alexander-Young Hello, and good morning everyone. Welcome to today's presentation.
Read More
Bears are Losing Control Over ProPhase Labs (PRPH), Here's Why It's a 'Buy' Now
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
ProPhase Labs (PRPH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read More
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
New York, NY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ: PRPH). The update note includes information on ProPhase's business model, services offered, industry outlook, financial results, management commentary, and risks.
Read More
ProPhase Labs Examines Strategic Opportunities to Leverage Its DTC Multi-Media Infrastructure with Telehealth Physician Networks for Prescription Drugs
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announces Ongoing Strategic Cost Cutting to Focus Resources on new DTC Marketing Initiatives to Drive Growth and Profitability Dispels rumors of an Investment Bank initiating a Capital Raise GARDEN CITY, NY, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and consumer products company provides a Company update and schedules a conference call for later today. Following the hiring of Stu Hollenshead, several new strategic opportunities have emerged for the Company to capitalize on its DTC multi-media expertise and infrastructure.
Read More
ProPhase Labs Announces Excellent Progress with Crown Medical Collections Targeting Over $50 Million in Net Near-Term Cash Recovery from COVID-19 Receivables
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Actively Pursuing Strategic Alternatives Including the Potential Sale of Nebula Genomics and DNA Complete to Unlock Immediate Cash GARDEN CITY, NY, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and consumer products company, is focused on immediate cash generation through two key initiatives: strategic alternatives including a potential sale of its genomics assets and the aggressive collection of outstanding COVID-19 receivables. These initiatives are expected to generate significant liquidity starting in the next few months and strengthen the company's balance sheet.
Read More
ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer products company, today announced the appointment of Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company's expansion into consumer-centered health and wellness products. As COO, Hollenshead will focus on accelerating ProPhase Labs' consumer-facing strategy, leveraging his deep expertise in direct-to-consumer growth, subscription models, digital marketing, and audience monetization to position the company as a leader in science-backed health solutions.
Read More
About ProPhase Labs, Inc. (PRPH)
- IPO Date 1994-04-04
- Website https://www.prophaselabs.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Ted William Karkus
- Employees 96